A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

First Implantations with MOVE-C Cervical Disc Prostheses from NGMedical

NGMedical GmbH located in Germany has announced the worldwide first implantations of its new MOVE-C disc prosthesis. After receiving CE approval end of December 2019, the first MOVE-C cervical disc prostheses were implanted in January.

The well thought through instrument set and the anatomical design of MOVE-C were crucial for the smooth surgeries. MOVE-C combines the features of a second generation disc prosthesis with the simple implantation technique of a cervical cage. The prosthesis offers physiological motion in all 6 planes including axial damping with progressive resistance to motion. Furthermore, MOVE-C is the first prosthesis with additively manufactured titanium endplates and avoids the use of PE.

NGMedical is specialized in motion preserving spinal implants as well as intelligent solutions for fusion surgery. With an experienced team of specialists and in cooperation with experienced spine surgeons NGMedical works on well thought through and tested solutions for state of the art spine surgery. In the near future, the new cervical BEE cage with a sophisticated honeycomb structure, which is purely manufactured additively, will be available.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The Evolut ™ FX+ TAVR system leverages market-leading valve performance with addition of larger windows to facilitate coronary access
The study was an analysis of AstraZeneca’s Phase 2 52-Week clinical trial of tralokinumab in patients with Idiopathic Pulmonary Fibrosis (IPF). The patient data from the trial was processed with Brainomix’s e-Lung tool. The tool is uniquely powered by the weighted reticulovascular score (WRVS), a novel biomarker that incorporates reticular opacities and vascular structures of the lung.
“Since the algorithm for matching patients with donors is changing across for all organs, this was a prime time to better understand whether transplant team decisions to accept a donated organ varied by patient race and gender,” she said. “We wanted to understand how the process of receiving a transplant after listing varied by race and gender, and the combination of the two, so that steps can be taken to make that process more equitable," said Khadijah Breathett, MD.
The Mount Sinai study found that primary care physicians’ approach reflects a dearth of evidence-based guidance for lung cancer screening shared decision-making in patients with complex comorbidities
This is the first ever transplantation of a genetically engineered porcine kidney into a living human recipient.

By using this website you agree to accept Medical Device News Magazine Privacy Policy